1. Report Industry Investment Rating - Not provided in the given content 2. Report's Core View - In 2025Q2, the proportion of pharmaceutical stocks held by public - offering funds increased, while the proportion of foreign - owned shares remained basically flat. Different pharmaceutical sub - industries showed varying trends in the proportion of heavy - position market value held by funds [2][8] 3. Summary by Relevant Catalogs 3.1 Pharmaceutical Industry Public - Offering Fund Holdings and Foreign - Owned Share Proportions - **Public - Offering Fund Holdings**: In 2025Q2, the proportion of all A - share public - offering funds in the pharmaceutical industry was 10.05%, a quarter - on - quarter increase of 0.82pp; after excluding active pharmaceutical funds, the proportion was 7.25%, a quarter - on - quarter increase of 0.90pp; after further excluding index funds, the proportion of pharmaceutical holdings was 7.38%, a quarter - on - quarter increase of 1.95pp. The proportion of the total market value of Shenwan pharmaceutical stocks was 6.32%, a quarter - on - quarter increase of 0.06pp [2][11] - **Foreign - Owned Shares**: In 2025Q2, the total market value of the pharmaceutical and biological sector held by Shanghai - Hong Kong and Shenzhen - Hong Kong Stock Connect accounted for 2.3%, a quarter - on - quarter decrease of 0.14pp, and the total market value of shares held was 149.11 billion yuan, a decrease of 0.3 billion yuan from the beginning of the period [8][12] 3.2 Pharmaceutical Sub - Industry Public - Offering Fund Holdings 3.2.1 Pharmaceutical Funds - **Top Three in Quarter - on - Quarter Increase**: Chemical preparations accounted for 42.3%, with the largest quarter - on - quarter increase of 17.5pp; other biological products accounted for 16.99%, a quarter - on - quarter increase of 9.9pp; medical R & D outsourcing accounted for 16.5%, a quarter - on - quarter increase of 5.5pp [5][18] - **Bottom Three in Quarter - on - Quarter Change**: Medical consumables accounted for 2.34%, a quarter - on - quarter change of - 0.36pp; offline pharmacies accounted for 0.4%, a quarter - on - quarter decrease of 0.11pp; pharmaceutical circulation accounted for 0.2%, a quarter - on - quarter increase of 0.02pp [5][18] 3.2.2 Non - Pharmaceutical Funds - **Top Three in Quarter - on - Quarter Increase**: Other biological products accounted for 0.54%, with the largest quarter - on - quarter increase of 0.23pp; chemical preparations accounted for 0.74%, a quarter - on - quarter increase of 0.11pp; traditional Chinese medicine accounted for 0.17%, a quarter - on - quarter increase of 0.02pp [6][24] - **Bottom Three in Quarter - on - Quarter Decrease**: Medical equipment accounted for 0.54%, a quarter - on - quarter decrease of 0.04pp; medical R & D outsourcing accounted for 0.23%, a quarter - on - quarter decrease of 0.04pp; medical consumables accounted for 0.15%, a quarter - on - quarter decrease of 0.04pp [6][24] 3.3 Pharmaceutical Companies by Public - Offering Fund Holdings 3.3.1 By Number of Holding Funds - **Top Five in Number of Holding Funds**: Hengrui Medicine (552 funds), WuXi AppTec (403 funds), Innovent Biologics (298 funds), Mindray Medical (274 funds), and 3SBio (208 funds) [4] - **Top Five in Increase of Number of Holding Funds in 2025Q2**: Yifang Biotech - U (increase of 84), Xintiandi (increase of 41), Baili Tianheng (increase of 36), Tigermed (increase of 32), and Rejing Bio (increase of 28) [33] - **Top Five in Decrease of Number of Holding Funds in 2025Q2**: Dong'e E - Jiao (decrease of 77), Aier Eye Hospital (decrease of 51), Aibo Medical (decrease of 43), Kanglong化成 (decrease of 33), and Changchun High - tech (decrease of 24) [35] 3.3.2 By Total Market Value of Holdings - **Top Five in Total Market Value of Holdings**: Hengrui Medicine (29.5 billion yuan), WuXi AppTec (27.7 billion yuan), Innovent Biologics (22.7 billion yuan), Mindray Medical (15.5 billion yuan), and Baili Tianheng (11.9 billion yuan) [4] - **Top Five in Increase of Total Market Value of Holdings in 2025Q2**: Huatai Medical (+9.78 billion yuan), Renfu Medicine (+9.38 billion yuan), Yunnan Baiyao (+6.7 billion yuan), New Industry (+5.08 billion yuan), and Fosun Pharma (+4.24 billion yuan) [4] - **Top Five in Decrease of Total Market Value of Holdings in 2025Q2**: Kanghong Pharmaceutical (-2.36 billion yuan), Alis ( - 2.03 billion yuan), BGI Genomics (-1.61 billion yuan), Xingqi Eye Drops (-1.45 billion yuan), and Aotai Biotech (-1.38 billion yuan) [41] 3.3.3 By Proportion of Circulating Shares Held - **Top Five in Proportion of Circulating Shares Held**: BeiGene - U (24.9%), Huatai Medical (22.9%), Zai Lab - U (22.6%), Haisco (22.4%), and 3SBio (21.0%) [4] - **Top Five in Increase of Proportion of Circulating Shares Held in 2025Q2**: BeiGene - U (+21.9pp), Yunnan Baiyao (+15.4pp), Zai Lab - U (+20.7pp), Haooubo (+12.3pp), and Shenzhou Cell (+12.0pp) [45] - **Top Five in Decrease of Proportion of Circulating Shares Held in 2025Q2**: Meihua Medical (-15.8pp), Kangwei Century (-14.5pp), San诺生物 (-12.1pp), Hitae Shinco (-11.7pp), and Dizal Pharma - U (-11.6pp) [47] 3.3.4 By Proportion of Total Shares Held - **Top Five in Proportion of Total Shares Held**: BeiGene - U (24.9%), Haisco (22.4%), 3SBio (17.1%), Zai Lab - U (15.7%), and United Imaging Healthcare (15.0%) [4] - **Top Five in Increase of Proportion of Total Shares Held in 2025Q2**: BeiGene - U (+21.9pp), Zai Lab - U (+15.0pp), United Imaging Healthcare (+12.0pp), Haisco (+14.3pp), and WuXi AppTec (+10.5pp) [51] - **Top Five in Decrease of Proportion of Total Shares Held in 2025Q2**: Hitae Shinco (-11.8pp), Aibo Medical (-10.5pp), Linuo Pharmaceutical Packaging (-10.3pp), San诺生物 (-9.6pp), and Huatai Medical (-9.5pp) [53]

Investment Rating - The report indicates a positive trend in the pharmaceutical sector, with public fund holdings increasing, suggesting a favorable investment outlook for the industry [3][10]. Core Insights - The pharmaceutical sector's public fund holdings reached 10.05% in Q2 2025, an increase of 0.82 percentage points (pp) from the previous quarter. Excluding active pharmaceutical funds, the holding percentage was 7.25%, up by 0.90 pp [3][10]. - The chemical preparation sub-sector saw the largest increase in public fund holdings, rising to 42.3%, an increase of 17.5 pp. Other biological products and medical research outsourcing also showed significant increases [4][19]. - The total market capitalization of the pharmaceutical sector was reported at 66,196 billion, with a market share of 6.32% in the overall A-share market [10][14]. Summary by Sections Public Fund Holdings - The total public fund holdings in the pharmaceutical sector increased to 10.05%, with a notable rise in the chemical preparation sector [3][10]. - The top five companies by public fund holdings include 恒瑞医药 (Hengrui Medicine) with 295 billion, 药明康德 (WuXi AppTec) with 277 billion, and 信达生物 (Innovent Biologics) with 227 billion [9][27]. Sub-sector Performance - The top three sub-sectors with increased market capitalization in public funds are: 1. Chemical preparations: 42.3%, +17.5 pp 2. Other biological products: 16.99%, +9.9 pp 3. Medical research outsourcing: 16.5%, +5.5 pp [4][19]. - The medical consumables sector saw a decrease to 2.34%, down by 0.36 pp, indicating a shift in investment focus [4][19]. Foreign Investment - Foreign investment in the pharmaceutical sector remained stable, with a total market value of 1491.1 billion, representing 2.3% of the sector [7][11]. Changes in Holdings - The report highlights significant changes in holdings, with 惠泰医疗 (Huitai Medical) seeing an increase of 97.8 billion in fund holdings, followed by 人福医药 (Renfu Pharmaceutical) with 93.8 billion [9][27].

Group 1 - The company announced an adjustment to the maximum repurchase price for its A-shares from 90.72 yuan to 114.15 yuan per share, while other details of the repurchase plan remain unchanged [1] - The company has approved a plan to repurchase A-shares using 1 billion yuan of its own and raised funds, with the aim of canceling and reducing registered capital [2] - As of July 28, the company has repurchased 6.5144 million A-shares, accounting for 0.23% of the total share capital, with a maximum price of 90.7 yuan and an average price of 76.34 yuan per share [2] Group 2 - In the first half of 2025, the company achieved operating revenue of 20.799 billion yuan, a year-on-year increase of 20.64%, and a net profit attributable to shareholders of 8.561 billion yuan, a year-on-year increase of 101.92% [6] - The chemical business segment reported the highest revenue growth of 33.51%, with total revenue of 16.301 billion yuan [6] - Revenue from U.S. clients reached 14.03 billion yuan, a year-on-year increase of 38.4%, while revenue from European clients was 2.33 billion yuan, a year-on-year increase of 9.2% [6] Group 3 - The company plans to distribute a cash dividend of 3.5 yuan for every 10 shares, totaling 1.003 billion yuan in cash dividends to all shareholders [7]

药明康德还宣布中期分红方案，共计约为10亿元，拟每10股派发现金红利3.5元。2025年以来，公司现 金分红与回购注销规模达到近70亿元。 新京报贝壳财经讯 药明康德（603259）发布2025年半年报，报告期内，公司实现营业收入207.99亿元， 同比增长20.64%；归属于上市公司股东的净利润85.6亿元，同比增长101.92%。 ...

尤为值得关注的是，今年以来，恒生港股通创新药精选指数年内累计上涨107.56%，领涨一众创新药指数。目前场内唯一跟踪该指数的港股通创新 药ETF（520880）今日场内价格豪涨5.06%，收盘涨幅霸居全市场所有ETF第一！ 基金经理丰晨成认为，港股+创新药是今年的主题主线，而不是短期概念炒作。行业周期向上趋势明显，这是今年创新药引领市场的根本原因，而 基本面财务数据出现明显回暖趋势，是源于创新药企扭亏为盈的企业越来越多，因为成本摊销都在研发早期，后期新药可销售后，其利润弹性更 大。 今日（7月29日）A股三大指数继续上涨，沪指站上3600点，深证成指与创业板指再创年内新高！沪深两市成交额达1.8万亿元，较昨日放量609亿 元。 盘面上，药明康德业绩亮眼，CXO全线沸腾，A股最大医疗ETF（512170）场内价格劲涨2.45%，成功斩获日线10连阳，刷新历史最长连阳纪录！ 或由于上海将发放6亿元算力券，光模块三巨头放量突破！中际旭创跳涨超9%股价创新高，新易盛涨超8%股价再创新高，成交额居A股首位，天 孚通信暴涨超13%放量突破！光模块含量突出的人工智能指数——创业板人工智能ETF（159363）场内价格收涨3 ...

Macro Dynamics - In the first half of the year, state-owned enterprises' total operating revenue decreased by 0.2% year-on-year, amounting to 4,074.96 billion yuan, while total profit fell by 3.1% to 218.25 billion yuan [1] - The taxes payable by state-owned enterprises also saw a decline of 0.8%, totaling 300.26 billion yuan [1] - As of the end of June, the asset-liability ratio of state-owned enterprises increased by 0.3 percentage points to 65.2% [1] Financial Institutions - Wang Xiaohang, former vice president of Ant Group, has been appointed as the Chief Technology Officer (CTO) of Ping An Group, bringing nearly 20 years of experience in the "finance + technology" sector [7] Market Data - The ChiNext Index rose by 1.86%, with strong performances in the pharmaceutical and steel sectors, while the overall market saw a trading volume exceeding 1.8 trillion yuan [8] - As of July 28, the financing balance on the Shanghai Stock Exchange reached 989.90 billion yuan, an increase of 11.71 billion yuan from the previous trading day [9] Company Dynamics - Apple announced the closure of its first direct store in Dalian, marking its first store closure in China, effective August 9, 2025 [11] - WuXi AppTec plans to adjust the upper limit of its share repurchase price from 90.72 yuan to 114.15 yuan per share, with its stock price rising significantly following the announcement [12] - Wanhua Chemical has resumed normal production at its facilities in Fujian after a maintenance shutdown [13] - China Chang'an Automobile has become the indirect controlling shareholder of Hunan Tianyan following a corporate restructuring [14] - Zhixiang Jintai received approval for clinical trials of its dual-specific antibody for passive immunity against rabies in children and adolescents [15]

把握中国龙头药企价值重估机遇，配置工具关注国内首只药ETF（562050）。聚焦A股50大龙头药企， 重仓创新药，兼顾高壁垒仿制药及中药，且完全不含医疗和CXO。 分析人士指出，药明康德上半年营业收入、净利润均创下历史新高，第二季度单季营收首次站上百亿元 台阶，达到111.45亿元。作为CXO"一哥"，逆势交出"最强"中报，向市场注入"强心剂"，并印证行业或 正加速回暖。 中金公司指出，如今创新药板块估值中枢上修，预期BD资金和二级热度上涨将反哺国内新药研发需求 起量以及一级创新药项目融资活跃度提升，内需CRO有望受益。另一方面，中国企业成本与效率优势 对海外客户具较强吸引力，外需CDMO订单趋势同样向好。 药明康德交出"史上最强"半年报，CXO板块沸腾！医疗ETF（512170）覆盖的6只CXO龙头股集体上 攻，药明康德涨7.72%，股价逼近100元，创3年新高！成交90.14亿元，位列A股第7。此外，九洲药业 涨停，昭衍新药午后触板。 中泰证券提示，随着财报陆续披露，CXO、GLP-1等景气赛道表现亮眼。后续建议继续重点关注有望逐 步走出拐点的细分板块，如CXO、科研上游等。 把握CXO、医疗器械拐点向上 ...

Market Overview - A-shares continued to rise, with the Shanghai Composite Index surpassing 3600 points and both the Shenzhen Component Index and the ChiNext Index reaching new highs for the year [1] - The total trading volume in the Shanghai and Shenzhen markets reached 1.8 trillion yuan, an increase of 609 billion yuan from the previous day [1] Sector Performance - WuXi AppTec reported strong earnings, leading to a surge in the CXO sector, with the largest medical ETF (512170) rising by 2.45%, achieving a record 10 consecutive days of gains [1] - The Hong Kong Stock Connect Innovation Drug ETF (520880) saw a significant increase of 5.06%, marking the highest gain among all ETFs in the market [1][5] Innovation Drug Sector - The Hang Seng Hong Kong Stock Connect Innovation Drug Index has risen by 107.56% year-to-date, outperforming other innovation drug indices [1] - Fund manager Feng Chen emphasized that the theme of Hong Kong stocks and innovative drugs is a long-term trend rather than a short-term speculative play, supported by a clear upward industry cycle [1][5] Policy and Economic Factors - Shanghai plans to issue 600 million yuan in computing power vouchers to reduce costs and support AI applications [2] - The Ministry of Industry and Information Technology held a meeting to discuss enhancing consumer goods supply and demand adaptability, promoting new industrial development, and improving standards in industries like photovoltaics [3] Investment Insights - Analysts suggest that the current bull market is being reinforced by increased capital inflows and improving fundamentals, with a focus on sectors like aviation equipment, wind power, and digital economy [3] - The CXO sector is expected to benefit from increased domestic demand for new drug research and development, as well as a favorable external environment for contract development and manufacturing organizations (CDMO) [12] AI and Computing Power Sector - The AI-focused ChiNext Artificial Intelligence ETF (159363) rose by 3.82%, reaching a new high, driven by strong performance in the optical module sector [1][14] - The optical module market is projected to grow significantly, with sales expected to reach 19.9 million units in 2025 and 33.5 million units in 2026, reflecting a robust growth trajectory [19] Company Highlights - WuXi AppTec reported a revenue of 20.799 billion yuan for the first half of the year, a year-on-year increase of 20.64%, with a net profit of 8.287 billion yuan, up 95.5% [10][12] - The company announced a mid-year dividend of 1 billion yuan and raised its full-year revenue growth forecast to 13%-17% [10][12]

今年以来，创新药迎来一波火热行情，赋能医药研发与生产的医药外包企业也出现回暖迹象。7月29日，医药外包龙头企业药明康德 （603259）交出了一份史上最强中报。 药明康德2025年半年度报告显示，公司上半年实现营业收入约为207.99亿元，同比增长20.64%；对应实现的归属净利润约为85.61亿 元，同比增长101.92%；扣非净利润约为55.82亿元，同比增长26.47%。公司营收、净利均创下历史新高。 | | | | 早刊: 九 川州: 八尺川 | | --- | --- | --- | --- | | 主要会计数据 | 本报告期 | 上年同期 | 本报告期比上 | | | (1-6月) | | 年同期增减(%) | | 营业收入 | 20,799,281,882.46 | 17,240,918,263.02 | 20.64 | | 利润总额 | 9.907.416.557.97 | 5.049.553.770.35 | 96.20 | | 归属于上市公司股东的净利润 | 8.560.882.627.56 | 4.239.822.013.11 | 101.92 | | 归属于上市公司股东的扣除非经常 | ...

Core Viewpoint - The A-share market is experiencing rapid sector rotation, with significant movements in the pharmaceutical sector and other industries, indicating strong trading activity and market dynamics [1][2]. Market Performance - The A-share market has stabilized above 3600 points, with the Shanghai Composite Index rising by 0.33%, the Shenzhen Component Index by 0.64%, and the ChiNext Index by 1.86% [11]. - The total trading volume in the Shanghai and Shenzhen markets reached 18,293 billion yuan, an increase of 632 billion yuan from the previous day, with over 2200 stocks rising [11]. Sector Highlights - The CRO (Contract Research Organization) sector saw significant gains, with companies like Ruizhi Pharmaceutical and Aoxiang Pharmaceutical hitting the daily limit, and WuXi AppTec reporting a 20.64% year-on-year increase in revenue to 20.8 billion yuan, with net profit soaring by 101.92% [11]. - The steel sector rebounded, with companies like Xining Special Steel and Bayi Steel reaching the daily limit, supported by high demand for manufacturing materials and low inventory levels [11]. - The optical communication sector also performed well, potentially influenced by Nvidia's increased orders for chips due to strong demand from China [3][11]. Investment Insights - The increase in transfer income has a significant positive impact on spending in categories such as clothing, housing, and healthcare, suggesting a potential shift in consumer behavior and spending patterns [2]. - Citigroup noted that the effectiveness of national subsidy programs on birth rates remains uncertain, as substantial financial support is necessary to offset the costs of raising children [2]. Fund Flow Dynamics - The net outflow of main funds was 240.05 billion yuan, with the largest outflow occurring in the non-ferrous metals sector, particularly affecting Northern Rare Earth [24]. - The top sectors for net inflow included pharmaceuticals, electronics, communications, and defense, indicating strong investor interest in these areas [24]. Notable Company Developments - WuXi AppTec announced an upward revision of its 2025 revenue guidance to 42.5-43.5 billion yuan, reflecting confidence in future growth [11]. - The semi-annual report from Shijia Photon showed a revenue increase of 121.12% year-on-year, with net profit soaring by 1712% [21]. Market Sentiment - The overall market sentiment appears cautious, with some investors expressing boredom due to the lack of new trading ideas and limited stock movements [5].